Caldera Medical, a Los Angeles-based medical device company has announced the completion of its acquisition of Atlantic Therapeutics, an Ireland-based medical device provider specializing in non-invasive pelvic floor strengthening and nerve-stimulating solutions. Caldera Medical specializes in products for the treatment of Stress Urinary Incontinence, Pelvic Organ Prolapse, Polyps, and Fibroids. The company is committed to improving the quality of life for women and has established close relationships with surgeons in the field. Atlantic Therapeutics’ products are backed by robust clinical evidence and have undergone randomized controlled trials. The company’s primary focus is on incontinence, sexual health dysfunctions, and related disorders.
The acquisition allows Caldera Medical to add Atlantic Therapeutics’ FDA-cleared Innovo product family to its portfolio. Innovo serves as a first-line therapy for women with stress urinary incontinence.
“We are thrilled to acquire Atlantic Therapeutics and scale the rapidly growing Innovo products worldwide,” said Bryon Merade, CEO of Caldera Medical, “This acquisition aligns perfectly with our mission and allows us to offer an even more comprehensive suite of solutions to healthcare providers and patients alike.”
“Since its formation, the team at Atlantic Therapeutics has demonstrated the huge potential of Innovo,” commented Susan Trent, CEO of Atlantic Therapeutics, “This unique technology with robust clinical data is ideally placed to serve the millions of women worldwide who suffer the daily distress of SUI. Caldera Medical’s ability to maximize this potential is the perfect next step. I am delighted that we will see Innovo thrive within Caldera Medical and want to thank Bryon and the team for their dedication to women’s health.”